PMID- 32714446
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 12
DP  - 2020
TI  - Serum concentration of asprosin in new-onset type 2 diabetes.
PG  - 65
LID - 10.1186/s13098-020-00564-w [doi]
LID - 65
AB  - BACKGROUND: Asprosin, a newly identified adipokine, is pathologically increased 
      in individuals with insulin resistance. However, the available evidence on the 
      association of asprosin and type 2 diabetes mellitus (T2DM) status is still 
      scarce. Therefore, this study aimed to determine the relationship between serum 
      concentrations of asprosin and T2DM status. METHODS: This observational study was 
      performed based on 194 adults (97 newly diagnosed T2DM and 97 healthy 
      individuals). Anthropometric and biochemical variables were determined in all 
      participants. Serum concentrations of asprosin were measured using enzyme-linked 
      immunosorbent assay (ELISA). RESULTS: In patients with T2DM, the serum 
      concentrations of asprosin were significantly higher than the healthy controls 
      (4.18 [IQR: 4.4] vs. 3.5 [IQR: 1.85], P < 0.001). The concentrations of asprosin 
      were significantly correlated with body mass index (BMI) and fasting blood 
      glucose (FBG) in healthy subjects and with BMI, FBG, hemoglobin A1c (HbA1c), 
      homeostatic model assessment of insulin resistance (HOMA-IR), and quantitative 
      insulin check index (QUICKI), triacylglycerol (TAG) and total 
      cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) ratio in the T2DM 
      group. In fully adjusted model, the odds ratio (OR) of T2DM with serum 
      concentrations of asprosin was approximately 1.547 (95% CI 1.293-1.850, 
      P < 0.001) compared to the control group. Multiple stepwise regression analysis 
      indicated that FBG and HOMA-IR were independently associated with asprosin in 
      T2DM. CONCLUSION: Our findings indicated that serum concentrations of asprosin 
      are increased in patients with T2DM. Also, asprosin is correlated with insulin 
      resistance and TC/HDL-C ratio (atherosclerotic risk factor of cardiovascular 
      diseases) in patients with T2DM.
CI  - (c) The Author(s) 2020.
FAU - Naiemian, Shakiba
AU  - Naiemian S
AD  - Department of Bitechnology, Sabzevar Branch, Islamic Azad University of Sabzevar, 
      Sabzevar, Iran. GRID: grid.449248.7
FAU - Naeemipour, Mohsen
AU  - Naeemipour M
AD  - Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, 
      Sabzevar, Iran. GRID: grid.412328.e. ISNI: 0000 0004 0610 7204
FAU - Zarei, Mehdi
AU  - Zarei M
AD  - Department of Physical Education and Sport Science, Faculty of Human Science, 
      University of Neyshabour, Neyshabour, Iran.
FAU - Lari Najafi, Moslem
AU  - Lari Najafi M
AD  - Pharmaceutical Sciences and Cosmetic Products Research Center, Kerman University 
      of Medical Sciences, Kerman, Iran. GRID: grid.412105.3. ISNI: 0000 0001 2092 9755
FAU - Gohari, Ali
AU  - Gohari A
AD  - Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, 
      Sabzevar, Iran. GRID: grid.412328.e. ISNI: 0000 0004 0610 7204
FAU - Behroozikhah, Mohammad Reza
AU  - Behroozikhah MR
AD  - Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, 
      Sabzevar, Iran. GRID: grid.412328.e. ISNI: 0000 0004 0610 7204
FAU - Heydari, Hafez
AU  - Heydari H
AD  - Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, 
      Sabzevar, Iran. GRID: grid.412328.e. ISNI: 0000 0004 0610 7204
FAU - Miri, Mohammad
AU  - Miri M
AD  - Non-Communicable Diseases Research Center, Department of Environmental Health, 
      School of Public Health, Sabzevar University of Medical Sciences, Sabzevar, Iran. 
      GRID: grid.412328.e. ISNI: 0000 0004 0610 7204
LA  - eng
PT  - Journal Article
DEP - 20200723
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC7376837
OTO - NOTNLM
OT  - Adipokine
OT  - Asprosin
OT  - Diabetes mellitus
OT  - Insulin resistance
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
PMCR- 2020/07/23
CRDT- 2020/07/28 06:00
PHST- 2020/02/25 00:00 [received]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
PHST- 2020/07/23 00:00 [pmc-release]
AID - 564 [pii]
AID - 10.1186/s13098-020-00564-w [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2020 Jul 23;12:65. doi: 10.1186/s13098-020-00564-w. 
      eCollection 2020.